At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34 enrolled
Drug / intervention
Oxymetazoline HCL 1% Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea
In Brief
A Phase 4 clinical trial evaluating The Vbeam® Prima System and Oxymetazoline HCL 1% Cream for Erythematotelangiectatic Rosacea. Completed, enrolled 34 participants across 2 sites.
Detailed Summary
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErythematotelangiectatic Rosacea
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedNov 2019
Primary CompletionNov 2020
Study CompletionJan 2021
TodayJul 2026
First PostedNov 6, 2019
Enrollment StartJan 15, 2019
Primary CompletionNov 13, 2020
Study CompletionJan 5, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.7 years ago
Interventions
The Vbeam® Prima Systemdevice
3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
Oxymetazoline HCL 1% Creamdrug
Daily application of Oxymetazoline HCL 1% cream for the 6-month study.